Literature DB >> 10811500

The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.

M Salden1, T A Splinter, H A Peters, M P Look, M Timmermans, J P van Meerbeeck, J A Foekens.   

Abstract

BACKGROUND: Urokinase-type plasminogen activator (uPA), its receptor (uPAR) and plasminogen activator inhibitors (PAI-1 and PAI-2), all play important roles in tumour invasion and metastasis. The tumour levels of the components of the urokinase-type plasminogen activator system (uPA-system) may help to identify individuals with a poor prognosis in postoperative non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: The levels of uPA, uPAR PAI-1 and PAI-2 were measured by enzyme-linked immunosorbent assay (ELISA) in triton-extracts, prepared from 88 NSCLC tissues (stage I-IIIa) and 74 normal lung tissues from the same patients.
RESULTS: The expression levels of uPA, uPAR, PAI-1 and PAI-2 were significantly higher in tumour tissues as compared to their normal equivalents (all, P < 0.0001). Significant relations were found between gender and uPA (P = 0.04) or uPAR (P < 0.001), and between PAI-2 and pathological stage (P = 0.03). For none of the studied factors of the uPA-system a significant relation with survival was found, neither in all patients, nor in the subgroups of patients with squamous-cell lung carcinoma or adenocarcinoma.
CONCLUSIONS: The expression levels of the components of the uPA-system were higher in NSCLC tissue as compared to normal lung tissue, but there were no significant relationships between their levels and survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811500     DOI: 10.1023/a:1008312801800

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  20 in total

1.  Plasminogen activator inhibitor-1 and susceptibility to lung cancer: a population genetics perspective.

Authors:  Aysegul Bayramoglu; Hasan Veysi Gunes; Muzaffer Metintas; Irfan Degirmenci; Halil Ibrahim Guler; Cengiz Ustuner; Ahmet Musmul
Journal:  Genet Test Mol Biomarkers       Date:  2014-06-23

2.  High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.

Authors:  Ross Smith; AiQun Xue; Anthony Gill; Christopher Scarlett; Alexander Saxby; Adele Clarkson; Thomas Hugh
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

3.  Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.

Authors:  Douglas M Evans; Kimberly D Sloan Stakleff
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.

Authors:  Qingyong Chen; Jun Fei; Lijun Wu; Zhongyong Jiang; Yuquan Wu; Yun Zheng; Guohua Lu
Journal:  Oncol Lett       Date:  2011-05-11       Impact factor: 2.967

5.  Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Jia-Ju Lu; Hong Guo; Bo Gao; Yun Zhang; Qing-Ling Lin; Jiang Shi; Jing-Jing Liu; Jian Liu
Journal:  Mol Clin Oncol       Date:  2017-11-03

6.  Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.

Authors:  C Ostheimer; C Evers; M Bache; T Reese; D Vordermark
Journal:  Strahlenther Onkol       Date:  2018-01-16       Impact factor: 3.621

7.  Protein signature of lung cancer tissues.

Authors:  Michael R Mehan; Deborah Ayers; Derek Thirstrup; Wei Xiong; Rachel M Ostroff; Edward N Brody; Jeffrey J Walker; Larry Gold; Thale C Jarvis; Nebojsa Janjic; Geoffrey S Baird; Sheri K Wilcox
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

8.  Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues.

Authors:  A C P Riddick; C J Shukla; C J Pennington; R Bass; R K Nuttall; A Hogan; K K Sethia; V Ellis; A T Collins; N J Maitland; R Y Ball; D R Edwards
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

9.  Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines.

Authors:  O Margalit; L Eisenbach; N Amariglio; N Kaminski; A Harmelin; R Pfeffer; M Shohat; G Rechavi; R Berger
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

10.  Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.

Authors:  Chia-Yi Su; Yu-Peng Liu; Chih-Jen Yang; Yuan-Feng Lin; Jean Chiou; Li-Hsing Chi; Jih-Jong Lee; Alex T H Wu; Pei-Jung Lu; Ming-Shyan Huang; Michael Hsiao
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.